Anaptysbio (ANAB) Debt Ratio (2016 - 2018)

Anaptysbio (ANAB) reported Debt Ratio of 0.0 for Q4 2018, down 94.65% on a YoY basis from 0.02 in Q4 2017, and down 73.34% quarter-over-quarter from 0.0 in Q3 2018.

Anaptysbio (ANAB) Debt Ratio (2016 - 2018) Analysis & Trends

Anaptysbio has reported Debt Ratio for 3 years, with the latest figure at 0.0 in Q4 2018.

  • For the quarter ending Q4 2018, Debt Ratio fell 94.65% year-over-year to 0.0; the trailing twelve-month figure through Dec 2018 stood at 0.0 (down 94.65% YoY), and the FY2018 full-year result was 0.0, down 94.65% from the prior year.
  • Debt Ratio for Q4 2018 stood at 0.0, down from 0.0 in the prior quarter.
  • The five-year high for Debt Ratio was 0.22 in Q4 2016, with the low at 0.0 in Q4 2018.
  • Historically, Debt Ratio has averaged 0.06 across 3 years, with a median of 0.02 in 2017.
  • The largest YoY upside for Debt Ratio was 80.88% in 2018 against a maximum downside of 94.65% in 2018.
  • Anaptysbio's Debt Ratio stood at 0.22 in 2016, then plunged by 89.67% to 0.02 in 2017, then sank by 94.65% to 0.0 in 2018.
  • The last three Debt Ratio figures came in at 0.0 (Q4 2018), 0.0 (Q3 2018), and 0.01 (Q2 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.18
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Anaptysbio 1.66 Bn 1.38 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2018 0.00
Sep 30, 2018 0.00
Jun 30, 2018 0.01
Mar 31, 2018 0.02
Dec 31, 2017 0.02
Sep 30, 2017 0.08
Jun 30, 2017 0.08
Mar 31, 2017 0.10
Dec 31, 2016 0.22